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Table 1. Distribution of Child–Pugh A and B patients among responding and
non-responding groups.
Child-Pugh A Child-Pugh B
RECIST
Non-responders 64 (92.8%) 12 (92.3%)
Responders 5 (7.2%) 1 (7.7%)
mRECIST
Non-responders 30 (43.5%) 5 (38.5%)
Responders 39 (56.5%) 8 (61.5%)
EASL
Non-responders 29 (42.0%) 5 (38.5%)
Responders 40 (58.0%) 8 (61.5%)
Letters to the Editorthere is an association between a single response and the more
clinically relevant end point of survival and demonstrated a
clear relationship, without the need for a conﬁrmatory scan.
Finally the reliability of EASL and mRECIST is questioned
because of the inﬂuence of lipiodol which makes the distinc-
tion between necrosis and vascularity difﬁcult in contrast
enhanced scans. In our study, patients did not receive lipiodol
and, in a previous meta-analysis, we have shown that there is
no clinical data to support its use [2]. Furthermore, the increas-
ing use of drug eluting beads as a more standardised and less
toxic method of delivering TACE [3] will allow the application
of mRECIST or EASL criteria without the confounding inﬂuence
of lipiodol.
We acknowledge that ours is a retrospective study which
requires prospective validation but were reassured by another
recently published retrospective study that conﬁrmed our
key ﬁndings that EASL and mRECIST are independent predictors
of overall survival in patients undergoing transarterial
embolisation [4]. A prospective validation is being undertaken
in the ongoing TACE 2 trial (ClinicalTrials.gov Identiﬁer
NCT01324076).226 Journal of Hepatology 201Conﬂict of interest
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London, UKThe ‘‘pegylated’’ story continues – Perhaps because
both ends (a2a and a2b) are true?To the Editor:
We want to comment on the article by Prati et al. [1] showing
decreased response rates to pegylated interferon (PegIFNa) 2b
plus ribavirin (RBV) in HCV patients with higher Ishak ﬁbrosis
stages (S0–2 vs. S3–4 vs. S5–6), while response rates to Peg-
IFNa2a + RBV remained similar (or – to be more precise – did not
signiﬁcantly decrease) across patient groups with mild (S0–2),
moderate (S3–4), and severe (S5–6) Ishak ﬁbrosis stages. In logis-
tic regression analysis, PegIFNa2b (vs. PegIFNa2a) treatment was
associated with treatment failure in patients with moderate to
advanced ﬁbrosis PS3 (OR 2.83) [1]. The data was derived from
a sub-analysis of the prospective MIST study [2], a trial that
was designed to compare safety and antiviral efﬁcacy of Peg-
IFNa2a + RBV vs. PegIFNa2b + RBV in patients with chronic HCV
infection. An important methodological ‘‘advantage’’ of the MISTstudy (compared to the IDEAL study [3]) is represented by the
fact that both patients on PegIFNa2a- and PegIFNa2b-based
treatments received exactly the same RBV dosing regimen, while
in the IDEAL study RBV was dosed according to the manufac-
turer’s instructions.
In this re-analysis of the MIST study [2], PegIFNa2a or Peg-
IFNa2b were randomly assigned to patient groups stratiﬁed
according to HCV genotype but not by ﬁbrosis stage. Even though
the prevalence of advanced ﬁbrosis (Ishak score S5 + 6) was sim-
ilar between patients treated with PegIFNa2a and PegIFNa2b, the
lack of stratiﬁcation according to ﬁbrosis stage may represent a
potential bias in baseline characteristics. In addition, only a small
subgroup of patients with advanced ﬁbrosis (S5–6) were included
in the MIST study (n = 43 in the PegIFNa2a group; n = 39 in the
PegIFNa2b group). Last but not least, IL28B single nucleotide2 vol. 57 j 221–232
Table 1. Comparison of the antiviral efﬁcacy of PegIFNa2a vs. PegIFNa2b in combination with ribavirin in HCV patients with METAVIR F4 cirrhosis.
PegIFNα2a + RBV PegIFNα2b + RBV p value
Patients, n 69 30
Cirrhosis METAVIR F4, n (%) 69 (100) 30 (100) n.a.
Gender [M/F] (%) 53/16 (77) 23/7 (77) 1.000
Age (yr) 49 ± 8 52 ± 10 0.344
Liver stiffness (kPa) 21.1 ± 15.6 24.0 ± 15.3 0.276
HVPG (mmHg) 10.7 ± 5.8 11.1 ± 5.7 0.520
IL28  C/C, n (%) 16 (23) 12 (40) 0.087
IL28  T/C or T/T, n (%) 53 (77) 18 (60) 0.087
HCV-GT 1 45 15 n.a.
HCV-GT 2 0 1 n.a.
HCV-GT 3 11 6 n.a.
HCV-GT 4 13 8 n.a.
HCV GT-1/4, n (%) 58 (84) 23 (77) 0.408
BL HCV-RNA >600,000 IU/ml, n (%) 38 (55) 18 (60) 0.646
Baseline HCV-RNA [log IU/ml] 5.94 ± 0.73 5.83 ± 0.57 0.448
Log drop at wk 2 [log IU/ml] 1.91 ± 1.33 1.38 ± 1.29 0.285
Log drop at wk 4 [log IU/ml] 2.32 ± 1.69 2.13 ± 1.80 0.270
Log drop at wk 8 [log IU/ml] 3.00 ± 2.15 3.62 ± 2.01 0.179
Log drop at wk 12 [log IU/ml] 3.56 ± 2.09 3.96 ± 2.27 0.193
RVR, n/n (%) 9/69 (13) 6/30 (20) 0.374
cEVR, n/n (%) 20/69 (29) 11/30 (37) 0.433
ETR, n/n (%) 30/69 (43) 14/30 (47) 0.714
SVR, n/n (%) 21/69 (30) 12/30 (40) 0.333
SVR GT 1/4, n/n (%) 16/58 (28) 7/23 (30) 0.840
SVR GT 2/3, n/n (%) 5/11 (45) 5/7 (71) 0.278
IL28  C/C
RVR, n (%) 5/16 (31) 3/12 (25) 0.730
SVR, n (%) 8/16 (50) 4/12 (33) 0.376
GT 1/4 - RVR, n (%) 2/12 (17) 2/9 (22) 0.776
GT 1/4 - SVR, n (%) 5/12 (42) 2/9 (22) 0.349
GT 2/3 - RVR, n (%) 3/4 (75) 1/3 (33) 0.317
GT 2/3 - SVR, n (%) 3/4 (75) 2/3 (67) 0.826
IL28  non-C/C
RVR, n (%) 4/53 (8) 2/18 (11) 0.699
SVR, n (%) 13/53 (25) 8/18 (44) 0.133
GT 1/4 - RVR, n (%) 3/46 (7) 1/14 (7) 1.000
GT 1/4 - SVR, n (%) 11/46 (24) 5/14 (36) 0.378
GT 2/3 - RVR, n (%) 1/7 (14) 1/4 (25) 0.659
GT 2/3 - SVR, n (%) 2/7 (29) 3/4 (75) 0.175
JOURNAL OF HEPATOLOGYpolymorphisms (SNPs) that have not been assessed in the MIST
study [2] – and have not been retrospectively re-tested – can clearly
inﬂuence response rates and could have introduced a bias in an
important baseline variable with direct inﬂuence on response
rates [1].
When taking a closer look at the data of the PegIFNa2a group,
a decrease in SVR rates from 71% in S0–2 to 53% in S5–6 patients
was also observed in patients treated with PegIFNa2a + RBV – aJournal of Hepatology 2difference of 18% in the SVR rate. Even if the SVR rates to Peg-
IFNa2a + RBV treatment are statistically not different between
patients with S0–2, S3–4, and S5–6, these differences would cer-
tainly be signiﬁcant if the number of included patients was
increased. In addition, an advanced ﬁbrosis stage was identiﬁed
as independent risk factor of treatment failure for both pegylated
interferons in combination with ribavirin for treatment of chronic
HCV infection [4,5].012 vol. 57 j 221–232 227
In contrast to SVR rates, RVR rates were similar in patients
treated with PegIFNa2b + RBV across ﬁbrosis stages. In this con-
text, it would be important to have more information about dose
reductions and early treatment discontinuations in the subgroups
with speciﬁc ﬁbrosis stages. Overall, more patients allocated to
the PegIFNa2b + RBV group had early treatment discontinuation
than in the PegIFNa2a + RBV group (n = 73 vs. n = 46). This higher
rate of treatment discontinuations in PegIFNa2b + RBV patients
despite similar rates of (S)AEs may also have biased SVR data
when comparing PegIFNa2a to PegIFNa2b patients.
Since the ‘‘hyporesponsiveness’’ to PegIFNa2b + RBV was
observed both in moderate (S3/4) and advanced (S5/6) stages of
ﬁbrosis [1], further data in other cohorts of cirrhotic patients
treated with different forms of PEGIFN (2a vs. 2b) are of clinical
interest. Since in the era of DAAs a PEGIFN + RBV ‘‘backbone’’ is
still needed, differences in response rates between PegIFNa2a
and PegIFNa2b used in triple therapies may then inﬂuence
response rates.
If PegIFNa2b + RBV performs worse than PegIFNa2a + RBV in
advanced ﬁbrosis, we would hypothesize that a difference may
be even more evident when restricting the comparison to cir-
rhotic patients with and without portal hypertension as included
in our recent study [6]. Thus, we re-analysed data from our pre-
vious study in cirrhotic (F4 METAVIR) patients [6]. This was a
prospective, non-randomized study including only patients with
histologically proven METAVIR F4 cirrhosis [6]. Since no clear evi-
dence of a difference in the efﬁcacy between PegIFNa2b and Peg-
IFNa2a was available, both types of pegIFN were used in
combination with RBV for antiviral therapy. A total of 99 patients
with METAVIR F4 cirrhosis were treated with PegIFNa2a + RBV
(n = 69) or with PegIFNa2b + RBV (n = 30). Baseline characteris-
tics and known predictors or treatment response (Table 1) were
similarly distributed between patients receiving PegIFNa2a-
and PegIFNa2b-based antiviral combination therapy. The addi-
tional information on IL28B SNP allowed us to perform subgroup
analysis in C/C and non-C/C patients to avoid potential bias
derived from potentially heterogeneous baseline characteristics
in the PegIFNa2a vs. PegIFNa2b groups. In patients with IL28B
C/C SNP, RVR (p = 0.730) and SVR (p = 0.376) rates were similar
between PegIFNa2a- and PegIFNa2b-based treatment groups.
Among patients with IL28B non-C/C SNP, PegIFNa2a + RBV
and PegIFNa2b + RBV treatments resulted in similar RVR
(p = 0.699) and SVR (p = 0.133) rates. Even in the most
difﬁcult-to-treat patients with IL28B non-C/C SNP and HCV-
GT1/4 infections, response rates were similar between
PegIFNa2a- and PegIFNa2b-treated patients, with SVR rates of
24% for PegIFNa2a + RBV and 36% for PegIFNa2b + RBV.
Our results have to be interpreted by considering all potential
problems of a post hoc analysis performed with data of a pro-
spective study that was not designed to demonstrate non-
inferiority of PegIFNa2b to PegIFNa2a (or vice versa). In addition,
the drug-compliance to PegIFNa2a/PegIFNa2b and potential bias
arising from problems with self-application of PegIFNa2a syrin-
Letters to the Editor228 Journal of Hepatology 2ges and PegIFNa2b pens by cirrhotic patients were not addressed
and should be investigated in prospective trials.
In summary, the recently published data of the MIST study by
Prati et al. [1] provide important information about virologic
response rates to PegIFN + RBV combination therapy among
patients with speciﬁc ﬁbrosis stages. Response rates were
reported to be lower in moderate and advanced ﬁbrosis when
using PegIFNa2b + RBV therapy but not if PegIFNa2a + RBV is
used [2]. In contrast, our analysis including data on HCV genotype
and IL28B SNPs did not show signiﬁcant differences in RVR and
SVR rates between patients receiving PegIFNa2a + RBV or Peg-
IFNa2b + RBV regimens.
Thus – if all known predictors of treatment response were
considered – no signiﬁcant differences in virologic response rates
between the two different types of pegylated interferons have
been demonstrated in any analysis so far.
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